{"id":"NCT00972738","sponsor":"Organon and Co","briefTitle":"Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235)","officialTitle":"A Multi-Center, Double-blind, Randomized, Parallel-Group Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis-Spring 2001 Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-04","primaryCompletion":"2001-07","completion":"2001-07","firstPosted":"2009-09-07","resultsPosted":"2010-06-16","lastUpdate":"2022-02-03"},"enrollment":1214,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":[]},{"type":"DRUG","name":"Comparator: loratadine","otherNames":[]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the treatment effect of montelukast versus placebo over a 2 week period in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active comparator.","primaryOutcome":{"measure":"Mean Change From Baseline in Daytime Nasal Symptoms Score Over the 2-week Treatment Period","timeFrame":"Baseline and over the 2-week treatment period","effectByArm":[{"arm":"Montelukast 10 mg","deltaMin":-0.38,"sd":null},{"arm":"Loratadine 10 mg","deltaMin":-0.47,"sd":null},{"arm":"Placebo","deltaMin":-0.29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["12602669"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":522},"commonTop":[]}}